(R)-N,N-Dimethyl-1-(morpholin-2-yl)methanamine, 95+%, 500mg

Methyl 4-formyl-2-methoxybenzoate, 96%, 100mg

anti-Desmoglein 1/2 mouse monoclonal, DG 3.10, 0.2 ml

1-methyl-3-{3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl}-1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 100mg

2-(3-cyclopentyl-1-propyn-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 95.0%, 1g

1-(tert-Butyl)-2-nitrobenzene, 95.0%, 100g

4-(Dimethylamino)nicotinic acid, 98.0%, 25g

Dimethyl Decahydro-2,6-naphthalenedicarboxylate (mixture of isomers)>98.0%(GC)5g

2,7-DIAZASPIRO[4.5]DECANE-7-CARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER, HCL, 95.0%, 100mg

(2-Bromo-5-methoxyphenyl)methanamine hydrochloride, 95.0%, 250mg

Hydroxy-PEG9-Boc, 5g

2-(Pyrrolidin-3-yl)-1,3,4-thiadiazole dihydrochloride, 97%, 500mg

5-[2(R)-[1(R)-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)morpholin-4-ylmethyl]-3,4-dihydro-2H-1,2,4-triazol-3-one, 98%, 25g